Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
about
Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Current and investigational treatment of psoriatic arthritis.Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.Guideline for anti-TNF-alpha therapy in psoriatic arthritis.Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Treat to target in psoriatic arthritis-evidence, target, research agenda.Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint.Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
P2860
Q33401933-985048B3-BC68-43B9-A02F-21B01EB8DB52Q35555905-7B68EB4E-0A1B-484E-A5BD-D67FED08E414Q35579352-E9ADBA3F-256C-4828-B016-BC51C8FC2942Q35579517-1C2D4548-087E-466D-9A26-8383DBB06277Q35638252-FFC9EF88-443C-4DC3-9EAB-920E782136F6Q35680654-02FF24F7-DC21-4FB4-8990-C50C39672CEBQ35731234-7A9E64F8-A0CC-4F5E-B05F-8ECA2CF2E0A5Q36032569-81809440-0562-4C0F-9336-8D9A413E4828Q37465349-8B0D3396-748E-40A4-B42F-6AB9763CC5E6Q37778661-EAE7FFF5-C9B0-477F-AD9E-C4AC4D6148D0Q37814549-F399E477-D0F6-416C-94CF-5A44EF24EA63Q38436516-10636B12-B60A-4810-AEF6-E3A31E0FEAFFQ42420342-EDF9347A-7D84-41A5-B85A-259147DCA9A5Q42955115-0C96AB32-C9C8-4094-BCA9-D1E2B59AEF66
P2860
Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Treatment of refractory psoria ...... vational study of 16 patients.
@ast
Treatment of refractory psoria ...... vational study of 16 patients.
@en
type
label
Treatment of refractory psoria ...... vational study of 16 patients.
@ast
Treatment of refractory psoria ...... vational study of 16 patients.
@en
prefLabel
Treatment of refractory psoria ...... vational study of 16 patients.
@ast
Treatment of refractory psoria ...... vational study of 16 patients.
@en
P2093
P2860
P356
P1476
Treatment of refractory psoria ...... vational study of 16 patients.
@en
P2093
P2860
P304
P356
10.1136/ARD.2003.006775
P407
P577
2004-02-01T00:00:00Z